Prakt. lékáren. 2008; 4(4): 162-165

Přehled současných moderních betablokátorů v léčbě kardiovaskulárních onemocnění

prof. MUDr. Jiří Vítovec CSc, prof. MUDr. Jindřich ©pinar CSc., FESC
I. interní kardioangiologická klinika FN u sv. Anny v Brně

Je podán přehled farmakologických vlastností betablokátorů, jejich rozdělení a hlavní indikace v léčbě kardiovaskulárních onemocnění. Na závěr jsou zmíněny neľádoucí účinky a kontraindikace.

Keywords: Klíčová slova: betablokátory, hypertenze, srdeční selhání, ICHS a arytmie.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, ©pinar J. Přehled současných moderních betablokátorů v léčbě kardiovaskulárních onemocnění. Praktické lékárenství. 2008;4(4):162-165.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Antonová P. Betablokátory. Remedia 2003; 13: 125-130. Go to original source...
    2. Bangalore S, Messerli F, Kostis J, Pepine C. Cardiovascular protection using betablockers. A critical review of the evidence. J Am Coll Cardiol 2007; 50: 563-572. Go to original source... Go to PubMed...
    3. Beevers DG. The end of beta blockers for uncomplicated hypertension? Lancet 2005; 366: 1510-1512. Go to original source... Go to PubMed...
    4. Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24: 2131-2141. Go to original source... Go to PubMed...
    5. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134: 550-560. Go to original source... Go to PubMed...
    6. Bultas J. Mizí daląí kontraindikace betablokátorů? JACC-CZ 2001; 3: 309-310.
    7. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684-1689. Go to original source... Go to PubMed...
    8. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13. Go to original source...
    9. Conrath ChE., Opthof T. Beta 3 - Adrenoceptors in the heart. Cardiovascular Res 2002; 56: 353-356. Go to original source... Go to PubMed...
    10. Dulin BR, Haas SJ, Abraham WT, Krum H. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of 12,000 patients in large-scale clinical trials. Am J Cardiol 2005; 95: 896-898. Go to original source... Go to PubMed...
    11. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
    12. ESH-ESC Task Force on the Management of Arterial Hypertension 2007 ESHESC Practice Guidelines for the Management of Arterial Hypertension. J Hypertension 2007, 25: 1751-1762. Go to original source... Go to PubMed...
    13. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153-1158. Go to original source... Go to PubMed...
    14. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among highrisk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-497. Go to original source... Go to PubMed...
    15. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146: 848-853. Go to original source... Go to PubMed...
    16. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281: 1927-1936. Go to original source... Go to PubMed...
    17. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1622-1632. Go to original source... Go to PubMed...
    18. Janouąek S. Betablokátory v klinické praxi. Causa subita 2003; 6: 461-465.
    19. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174: 1737-1742. Go to original source... Go to PubMed...
    20. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553. Go to original source... Go to PubMed...
    21. Linhart A, Goláň L, Aschermann M. Betablokátory v léčbě arteriální hypertenze. Proč patří mezi léky prvé volby? Kardiol Rev 2001; 3: 186-192.
    22. López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341-1362. Go to original source... Go to PubMed...
    23. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as firstline therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903-1907. Go to original source... Go to PubMed...
    24. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-2199. Go to original source... Go to PubMed...
    25. ©pinar J, Vítovec, et al. Ischemická choroba srdeční Praha: Grada, 2003: 361 s.
    26. Vítovec J, ©pinar J. Betablokátory v léčbě chronického srdečního selhání. Jak převést výsledky klinických studií do lékařské praxe. Vnitřní lék. 2000; 46: 161-165.
    27. Vítovec J, ©pinar J, et al. Farmakoterapie kardiovaskulárních onemocnění 2. vydání. Praha: Grada, 2004: 248 s.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.